Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allergen specific immunotherapy for atopic dermatitis.

Natalija Novak1

  • 1Department of Dermatology, University of Bonn, Bonn, Germany. Natalija.Novak@ukb.uni-bonn.de

Current Opinion in Allergy and Clinical Immunology
|November 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eczematous component in psoriasis is possibly a negative prognostic factor for deucravacitinib treatment outcome.

Dermatology (Basel, Switzerland)·2026
Same author

Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross-sectional study.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Insights into Api m 10-Isoforms and Splice Variants: More Than One Major IgE-Binding Epitope.

Clinical and translational allergy·2026
Same author

Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study.

Dermatology and therapy·2025
Same author

Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesions.

Frontiers in immunology·2025
Same author

The respiratory allergy patient's healthcare journey: An international qualitative survey employing an ethnographic approach.

The World Allergy Organization journal·2025
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Allergen specific immunotherapy shows promising results for treating atopic dermatitis. Further research into this causal therapy could offer new treatment options for patients with atopic dermatitis.

Area of Science:

  • Immunology
  • Dermatology
  • Allergology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition.
  • The role of allergen specific immunotherapy (AIT) in AD management remains debated.
  • Limited high-quality studies exist on AIT's efficacy and safety in AD.

Purpose of the Study:

  • To review recent advancements in AIT for atopic dermatitis.
  • To evaluate the advantages and disadvantages of AIT in specific AD patient subgroups.
  • To explore the potential of AIT as a causal treatment for AD.

Main Methods:

  • Systematic literature review of published studies on AIT in atopic dermatitis.
  • Analysis of recent double-blind, placebo-controlled studies.
  • Evaluation of immunologic and clinical outcomes.

Related Experiment Videos

Main Results:

  • AIT for atopic dermatitis yields promising results.
  • Evidence suggests AIT may improve AD severity and course in select patients.
  • Recent controlled studies support the efficacy of subcutaneous and sublingual AIT.

Conclusions:

  • AIT is a potential causal therapy for sensitizations in atopic dermatitis.
  • Promising immunologic and clinical changes are observed with AIT in AD patients.
  • Future research and clinical studies are crucial for establishing AIT as a standard AD treatment.